A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

NCT06241950 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Study is being terminated due to a business decision.

Conditions

Duchenne Muscular Dystrophy

Interventions

GENETIC: delandistrogene moxeparvovec
BIOLOGICAL: imlifidase

Sponsor

Sarepta Therapeutics, Inc.

Collaborators

[object Object]